Brind.

Steve Cohen recommended Genmab as a buy, and Truist Securities raised its price target for the company.

1 report, 1 independent Updated Jul 25

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Genmab Steve Cohen

Keep exploring

The entities involved

Genmab
Danish healthcare company
- Genmab, a Danish biotechnology company, granted stock units and warrants via its Board of Directors on September 1, 2026.Thu 21:07
Steve Cohen
researcher (ORCID 0000-0002-9471-4586)

Nothing else this week.

Related events

Truist Financial started coverage on Genmab shares, and TD Cowen raised rating and price target for the company, which trades on Nasdaq.Sep 9

Coverage

Newest first; wire copies grouped

Jul 25Insider MonkeyTruist Securities Hikes Genmab A/S (GMAB) Price Target Buoyed by Revenue Outlook Genmab A/S (NASDAQ:GMAB) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 8, Tru